AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company at the following investor conferences during the month of September:

  • Morgan Stanley Global Healthcare Unplugged Conference on September 13 at 1:35 p.m. ET
  • Robert W. Baird 2010 Healthcare Conference on September 14, at 9:30 a.m. ET
  • UBS 2010 Global Life Sciences Conference on September 22, at 2:00 p.m. ET

The conferences are being held in New York City.

A live webcast of each presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral contrast agent used in magnetic resonance imaging. For additional company information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.



CONTACT:

AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Professional Services  Finance

MEDIA:

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.